NasdaqGM:MIRMBiotechs
Is Mirum’s BLOOM Fragile X Trial Expanding a Durable Neurology Strategy for Mirum Pharmaceuticals (MIRM)?
Mirum Pharmaceuticals recently reported that it has enrolled the first participant in its BLOOM Phase 2 clinical study of MRM-3379 for Fragile X syndrome, a serious inherited neurodevelopmental condition with no approved treatments.
This milestone moves Mirum’s rare disease pipeline further into neurology, highlighting how the company is testing its approach beyond liver-focused indications.
We’ll now examine how launching the BLOOM Phase 2 Fragile X program could influence Mirum’s...